Cunning Capital Partners’s Edwards Lifesciences EW Stock Holding History

Cunning Capital Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,500	Closed	-$6.15M	–	37
2021 Q4	$6.15M	Sell	4,500 -63,000	-93%	-$7.35M	3.35%	17
2021 Q3	$7.64M	Hold	67,500	–	–	4.02%	5
2021 Q2	$6.99M	Hold	67,500	–	–	3.64%	6
2021 Q1	$5.65M	Hold	67,500	–	–	3.52%	5
2020 Q4	$6.16M	Hold	67,500	–	–	3.29%	16
2020 Q3	$5.39M	Hold	67,500	–	–	3.41%	12
2020 Q2	$4.67M	Sell	67,500 -16,500	-20%	-$1.17M	3.29%	15
2020 Q1	$5.28M	Buy	+84,000	New	+$6.06M	4.88%	8

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cunning Capital Partners's EW Position: Q1 2022 in Review

Cunning Capital Partners sold out of Edwards Lifesciences (EW) in Q1 2022, closing a stake of 4,500 shares — an estimated $6.15M sold.

Cunning Capital Partners first reported a position in EW in Q1 2020 and held it in 8 quarters. The position peaked at $7.64M in Q3 2021. 1,312 funds tracked by Wall St. Rank hold EW as of Q1 2022.

Cunning Capital Partners reported no remaining Edwards Lifesciences position as of Q1 2022 after selling out during the quarter.
Cunning Capital Partners sold 4,500 Edwards Lifesciences shares in Q1 2022, an estimated $6.15M.
Cunning Capital Partners first reported a position in Edwards Lifesciences in Q1 2020 and held it in 8 quarters.
Cunning Capital Partners's Edwards Lifesciences position peaked at $7.64M in Q3 2021.
1,312 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Cunning Capital Partners's 13F filing for Q1 2022, filed 9 May 2022.